Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea for Sickle Cell Anemia in DRC
NCT05681598Completed
- Sponsor
- Université de Kinshasa
- Start
- Aug 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Université de Kinshasa. Primary endpoints: Body Mass Index at 2 years, Frequency of Acute Clinical Events at 2 years and 9 more. Started Aug 2017; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT05681598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681598.